Kyowa Hakko Kirin Co., Ltd. has completed the construction of an biopharmaceutical API manufacturing facility at its Takasaki site in Japan. The company invested 6 billion yen ($58.8 million) for the facility, which includes  a 12,000-L bioreactors for recombinant animal cells as well as a purification facility with a large column. Operations are scheduled to begin the first half of 2016. 

Source: Kyowa Hakko Kirin